Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Lingo01:11

Genetic Lingo

Overview
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: frequency of surveillance and survival in hepatocellular carcinoma.

Alimentary pharmacology & therapeutics·2018
Same author

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.

Alimentary pharmacology & therapeutics·2018
Same author

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.

Alimentary pharmacology & therapeutics·2017
Same author

Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Alimentary pharmacology & therapeutics·2016
Same author

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

Journal of viral hepatitis·2016
Same author

Editorial: improved understanding of the epidemiology of primary biliary cirrhosis in South Korea.

Alimentary pharmacology & therapeutics·2016
Same journal

How to become a centenarian in four weeks?. Myths and limits of longevity recipes: a critical review.

Minerva medica·2026
Same journal

Comparative efficacy and safety between intravenous recombinant human prourokinase and alteplase in acute ischemic stroke treatment: a meta-analysis of randomized controlled trials.

Minerva medica·2026
Same journal

Efficacy and safety of oral tapentadol for cancer-related pain: an updated systematic review and meta-analysis.

Minerva medica·2026
Same journal

Use of the neurostimulator in thyroidectomy procedures: comparison between vagal and recurrent laryngeal nerve stimulation.

Minerva medica·2026
Same journal

Iron deficiency and risk of acute kidney injury after TAVI: a machine learning analysis.

Minerva medica·2026
Same journal

Therapeutic adherence and health literacy: a perfect match in dyslipidemic patients.

Minerva medica·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Hereditary hemochromatosis.

O K Fix1, K V Kowdley

  • 1Division of Gastroenterology, University of California, San Francisco, CA, USA.

Minerva Medica
|November 27, 2008
PubMed
Summary
This summary is machine-generated.

Hereditary hemochromatosis (HH) is an iron overload disorder. Early diagnosis and iron depletion through phlebotomy can prevent severe complications and ensure normal survival for patients.

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Related Experiment Videos

Last Updated: Jun 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Hematology

Background:

  • Hereditary hemochromatosis (HH) encompasses inherited iron metabolism disorders causing tissue iron overload.
  • Classical HH links to HFE gene mutations, prevalent in Northern European populations.
  • Non-HFE HH involves mutations in other iron metabolism genes, with hepcidin dysfunction implicated in most forms.

Purpose of the Study:

  • To review the pathophysiology, clinical manifestations, diagnosis, and management of hereditary hemochromatosis.
  • To highlight the role of hepcidin in iron regulation and its dysfunction in HH.
  • To discuss the implications of HH on various organ systems and long-term patient outcomes.

Main Methods:

  • Review of existing literature on hereditary hemochromatosis.
  • Analysis of genetic mutations associated with classical and non-HFE HH.
  • Examination of the clinical presentation, diagnostic criteria, and treatment strategies for HH.

Main Results:

  • HH affects organs like the liver, heart, and pancreas, with cirrhosis and diabetes as late signs.
  • Successful iron depletion via phlebotomy before significant organ damage leads to normal survival.
  • HH exhibits incomplete penetrance and variable expressivity, with women generally less affected than men.

Conclusions:

  • Defective hepcidin function is central to most HH forms.
  • Early diagnosis through genetic testing and elevated transferrin saturation is crucial.
  • Phlebotomy is the standard treatment; population screening remains controversial due to variable penetrance.